日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degrader with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer

Imlunestrant 是一种口服、脑渗透性选择性雌激素受体降解剂,对 ESR1 野生型和突变型乳腺癌具有强效抗肿瘤活性

Shripad V Bhagwat #, Cecilia Mur #, Matthew Vandekopple #, Baohui Zhao, Weihua Shen, Carlos Marugán, Andrew Capen, Lisa Kindler, Jennifer R Stephens, Lysiane Huber, Mark A Castanares, David Garcia-Tapia, Jeff D Cohen, Jolie Bastian, Brian Mattioni, Eunice Yuen, Thomas K Baker, Vivian Rodriguez Cruz,

Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL

2024年淋巴瘤研究基金会研讨会关于慢性淋巴细胞白血病(CLL)或小淋巴细胞淋巴瘤(SLL)治疗选择和顺序的共识建议

Soumerai, Jacob D; Barrientos, Jacqueline; Ahn, Inhye; Coombs, Catherine; Gladstone, Douglas; Hoffman, Marc; Kittai, Adam; Jacobs, Ryan; Lipsky, Andrew; Patel, Krish; Rhodes, Joanna; Skarbnik, Alan; Thompson, Meghan; Ermann, Daniel; Reville, Patrick; Shah, Harsh; Brown, Jennifer R; Stephens, Deborah M

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

阿卡替尼治疗初治慢性淋巴细胞白血病

Byrd, John C; Woyach, Jennifer A; Furman, Richard R; Martin, Peter; O'Brien, Susan; Brown, Jennifer R; Stephens, Deborah M; Barrientos, Jacqueline C; Devereux, Stephen; Hillmen, Peter; Pagel, John M; Hamdy, Ahmed; Izumi, Raquel; Patel, Priti; Wang, Min Hui; Jain, Nitin; Wierda, William G

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells

PIM 和 CDK4/6 的联合抑制可抑制 mTOR 信号传导和 Rb 磷酸化,并增强癌细胞中的 PI3K 抑制

Lacey M Litchfield, Karsten Boehnke, Manisha Brahmachary, Cecilia Mur, Chen Bi, Jennifer R Stephens, J Michael Sauder, Sonia M Gutiérrez, Ann M McNulty, Xiang S Ye, Wenjuan Wu, María José Lallena, Xueqian Gong, Farhana F Merzoug, Valerie M Jansen, Sean G Buchanan

Broad Spectrum Activity of the Checkpoint Kinase 1 Inhibitor Prexasertib as a Single Agent or Chemopotentiator Across a Range of Preclinical Pediatric Tumor Models

检查点激酶 1 抑制剂 Prexasertib 作为单一药物或化学增强剂对一系列临床前儿科肿瘤模型的广谱活性

Caitlin D Lowery, Michele Dowless, Matthew Renschler, Wayne Blosser, Alle B VanWye, Jennifer R Stephens, Philip W Iversen, Aimee Bence Lin, Richard P Beckmann, Kateryna Krytska, Kristina A Cole, John M Maris, Douglas S Hawkins, Brian P Rubin, Raushan T Kurmasheva, Peter J Houghton, Richard Gorlick, 

MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping

MET 靶向抗体 (emibetuzumab) 和激酶抑制剂 (merestinib) 作为单一药物或联合用于治疗 MET 外显子 14 跳跃的癌症模型

S Betty Yan, Suzane L Um, Victoria L Peek, Jennifer R Stephens, Wei Zeng, Bruce W Konicek, Ling Liu, Jason R Manro, Volker Wacheck, Richard A Walgren

LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth

LY2875358 是一种中和和内化抗 MET 二价抗体,可抑制 HGF 依赖性和 HGF 非依赖性的 MET 活化和肿瘤生长

Ling Liu, Wei Zeng, Mark A Wortinger, S Betty Yan, Paul Cornwell, Victoria L Peek, Jennifer R Stephens, Jonathan W Tetreault, Jinqi Xia, Jason R Manro, Kelly M Credille, Darryl W Ballard, Patricia Brown-Augsburger, Volker Wacheck, Chi-Kin Chow, Lihua Huang, Yong Wang, Irene Denning, Julian Davies, Y

Therapeutic inhibition of MAP kinase interacting kinase blocks eukaryotic initiation factor 4E phosphorylation and suppresses outgrowth of experimental lung metastases

MAP 激酶相互作用激酶的治疗性抑制可阻断真核起始因子 4E 磷酸化并抑制实验性肺转移的生长

Bruce W Konicek, Jennifer R Stephens, Ann M McNulty, Nathaniel Robichaud, Robert B Peery, Chad A Dumstorf, Michele S Dowless, Philip W Iversen, Stephen Parsons, Karen E Ellis, Denis J McCann, Jerry Pelletier, Luc Furic, Jonathan M Yingling, Louis F Stancato, Nahum Sonenberg, Jeremy R Graff